Skip to main content

Table 2 The 1-year/2-year relapse rates according to RRM1 expression and clinicopathological features

From: RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy

 

No

1-y Ra rate (%)

p

2-y Ra rate (%)

p

RRM1 level

 Low

64

0

0.009

3.1%

0.005

 High

17

17.7%

 

29.4%

 

 Unknown

81

6.2%

 

11.1%

 

Gender

 Female

30

13.3%

0.040

13.3%

0.500

 Male

132

3.0%

 

9.1%

 

Age (years)

  ≤ 60

85

4.7%

0.569

10.6%

0.75

  > 60

77

5.3%

 

9.1%

 

Weight (Kg)

  ≤ 65

78

13.3%

0.204

7.7%

0.369

  > 65

84

4.8%

 

11.9%

 

ECOG Score

 0–1

157

5.1%

0.774

10.2%

0.452

 2

5

0

 

0

 

CUA/EAU risk group

 2

54

1.9%

0.271

11.1%

0.710

 3

108

6.5%

 

9.3%

 
  1. R: means relapse
  2. p < 0.05 is set in boldface